SS-31 Peptides 99% Hight purity Weight Loss Peptide
9 Inquiries
796043-06-6
Pharmaceutical Grade
99%
ningbo
111
2mg 5mg 10mg 20mg 30mg
2030-12-31
peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
Peptide
CAS No.:796043-06-6
Molecular Formula:C21H30N2O6S
Molecular Weight:438.54
Categories:
Characteristics-
Density:
1.373±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
Boiling Point:605.408±63.00 °C(Press: 760.00 Torr)(predicted)
PKA:14.773±0.10(predicted)
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptide
-
Location:
Hangzhou Peijia E-commerce Co., LTD
-
Year of Establishment:
2026
-
-
Inquiry History9 Inquiries
Country Product Purchase Quantity Date Posted
United States
Retatrutide 10mg Retatrutide 10mg
10 MT May 16, 2026
United States
Retatrutide 10 mg
10 MG Mar 4, 2026
Hongkong, China
Peptide
10000 MT Jan 6, 2026
United States
Peptide
1 MT Feb 13, 2026
United States
Peptide
100 Jan 28, 2026
Greenland
Peptide
10 MG Sep 2, 2026
Ireland
retatrutide 10mg
10 Mar 27, 2026
Canada
Peptide
10 G Mar 1, 2026
Canada
Peptide
1 MT Feb 24, 2026 Post an enquiry for this product